Read about the results of a research study comparing recombinant influenza vaccine with standard-dose influenza vaccine in adults less than 65 years of age.

Find invaluable vaccination tips shared during the VEC team’s interactions with healthcare providers at local and national conferences.

CHOP is on the forefront of investigating the design and delivery of gene therapies to curb and potentially cure congenital diseases.

CHOP’s “Advancing Craniofacial Treatment with Genomics and Gene Therapy” Frontier Program is poised to harness genomic technologies to spearhead innovations in gene therapy, improve diagnostics, predict treatment outcomes and develop new therapies for children.

Our innovative fetal patient registry and data management system has made remarkable strides impacting both clinical care and research.

Expanded criteria for FETO procedure and transition to exclusively using muscle flap repair.

In its first year, our Newborn/Infant Intensive Care Unit at CHOP’s Middleman Family Pavilion in King of Prussia had over 250 admissions and expanded from 10 beds to 18.

An experimental gene therapy, studied in a preclinical model of Batten disease, was found to slow symptoms and extend lifespan

Researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania unlocked important new insights in how the immune system selects the right signals to alert T cells, a vital step in the prevention and treatment of serious illness. The findings were published in the journal Proceedings of the National Academy of Sciences (PNAS).

A report estimates that vaccines were directly responsible for a 40% decrease in infant deaths over the last 50 years. Find out more. You'll also learn about the rates of long COVID and about antibiotic-resistant bacteria in Ukraine.